Eli Lilly joins SNM imaging network

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 5
Volume 19
Issue 5

Eli Lilly has joined SNM’s Clinical Trials Network, a collaborative effort designed to address the need for validated imaging biomarkers for streamlining the development and registration of investigational therapeutics.

Eli Lilly has joined SNM's Clinical Trials Network, a collaborative effort designed to address the need for validated imaging biomarkers for streamlining the development and registration of investigational therapeutics.

The network also applies for and holds FDA new drug applications that will be available for cross-reference in multicenter clinical trials of imaging agents to assess response to treatment or to stratify patients for enrollment in clinical trials. "Eli Lilly seeks to improve patient outcomes by accelerating our therapeutic pipeline by using molecular imaging," said Johannes Tauscher, MD, a medical fellow and head of the translational imaging group at the company.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
2 experts in this video